Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond L Benza

Showing results (11-20 of 209) with videos related to

Pageof 21
Sort By:
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 25, 2020
Ethical considerations of thoracic transplant and circulatory support during the COVID-19 pandemic: A closer look at pulmonary vascular diseaseElisa A Bradley, Athénaïs Boucly, Raymond L Benza
Pulmonary Circulation|December 23, 2020
Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertensionNathan J Verlinden, Raymond L Benza, Amresh Raina
Chest|September 11, 2024
Risk Stratification in Pulmonary Hypertension: We Need to "GoDeeper"!Charles Fauvel, Mardi Gomberg-Maitland, Raymond L Benza
American Journal of Respiratory and Critical Care Medicine|May 21, 2026
Reply to Blette and Kawut: Surrogate Endpoints are Risky Business in Pulmonary Arterial HypertensionShili Lin, R James White, Raymond L Benza
Pulmonary Circulation|July 4, 2017
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case seriesAmresh Raina, Raymond L Benza, Harrison W Farber
The Lancet. Respiratory Medicine|February 29, 2024
Risk scores as a surrogate in pulmonary arterial hypertension: a different lensR James White, Daniel J Lachant, Raymond L Benza
Pulmonary Circulation|June 10, 2017
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertensionRyan Davey, Raymond L Benza, Srinivas Murali, et al.
Journal of Pharmacy Practice|September 11, 2020
A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to SelexipagNathan J Verlinden, Claire Walter, Amresh Raina, et al.
Infectious Disease Reports|January 29, 2014
Concomitant cat scratch disease and squamous cell carcinoma in a cardiac transplantNitin Bhanot, George G Sokos, Raymond L Benza, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 8, 2021
Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art reviewMichael Wesley Milks, Sandeep Sahay, Raymond L Benza, et al.
Pageof 21

Showing results (11-20 of 209) with videos related to

Sort By:
Pageof 21
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 25, 2020
Ethical considerations of thoracic transplant and circulatory support during the COVID-19 pandemic: A closer look at pulmonary vascular diseaseElisa A Bradley, Athénaïs Boucly, Raymond L Benza
Pulmonary Circulation|December 23, 2020
Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertensionNathan J Verlinden, Raymond L Benza, Amresh Raina
Chest|September 11, 2024
Risk Stratification in Pulmonary Hypertension: We Need to "GoDeeper"!Charles Fauvel, Mardi Gomberg-Maitland, Raymond L Benza
American Journal of Respiratory and Critical Care Medicine|May 21, 2026
Reply to Blette and Kawut: Surrogate Endpoints are Risky Business in Pulmonary Arterial HypertensionShili Lin, R James White, Raymond L Benza
Pulmonary Circulation|July 4, 2017
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case seriesAmresh Raina, Raymond L Benza, Harrison W Farber
The Lancet. Respiratory Medicine|February 29, 2024
Risk scores as a surrogate in pulmonary arterial hypertension: a different lensR James White, Daniel J Lachant, Raymond L Benza
Pulmonary Circulation|June 10, 2017
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertensionRyan Davey, Raymond L Benza, Srinivas Murali, et al.
Journal of Pharmacy Practice|September 11, 2020
A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to SelexipagNathan J Verlinden, Claire Walter, Amresh Raina, et al.
Infectious Disease Reports|January 29, 2014
Concomitant cat scratch disease and squamous cell carcinoma in a cardiac transplantNitin Bhanot, George G Sokos, Raymond L Benza, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 8, 2021
Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art reviewMichael Wesley Milks, Sandeep Sahay, Raymond L Benza, et al.
Pageof 21